Literature DB >> 8813280

Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients.

P M Andersen1, L Forsgren, M Binzer, P Nilsson, V Ala-Hurula, M L Keränen, L Bergmark, A Saarinen, T Haltia, I Tarvainen, E Kinnunen, B Udd, S L Marklund.   

Abstract

We describe 36 patients (six were apparently sporadic cases and 30 were cases from nine families) with amyotrophic lateral sclerosis (ALS) characterized by a distinct phenotype associated with homozygosity for an Asp90Ala mutation in the CuZn-superoxide dismutase gene. The presenting motor manifestation in all patients was paresis in the legs, with slow progression to the upper extremities and finally to the bulbar muscles. The age of ALS onset varied from 20 to 94 years, with a mean of 44 years. Mean survival time was 13 years for the 11 deceased patients. However, this is probably biased and untypical (low) when compared with the disease duration in the surviving patients, and when considering other medical complications in the deceased patients. The rate of progression was highly variable, even within families. All patients showed signs of involvement of both upper and lower motor neurons. Other neurological features included painful muscle spasms and paraesthesiae in the lower extremities. Two-thirds of patients experienced difficulty with micturition. Electrophysiological studies confirmed the slow progression and spatial distribution of clinical symptoms in the peripheral motor system. Furthermore, [corrected] potentials evoked by transcranial magnetic stimulation (MEP) were compared with those evoked by cervical or lumbosacral electrical stimulation and often revealed marked slowing of transmission in central motor pathways. In Sweden and Finland ALS patients homozygous for the Asp90Ala mutation constitute a phenotypically characteristic subset of motor neuron disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813280     DOI: 10.1093/brain/119.4.1153

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  62 in total

Review 1.  Progress in the pathogenesis of amyotrophic lateral sclerosis.

Authors:  C E Shaw; A al-Chalabi; N Leigh
Journal:  Curr Neurol Neurosci Rep       Date:  2001-01       Impact factor: 5.081

Review 2.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

Review 3.  Familial Amyotrophic Lateral Sclerosis.

Authors:  Kevin Boylan
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

4.  Homozygous SMN2 deletion is a protective factor in the Swedish ALS population.

Authors:  Philippe Corcia; Caroline Ingre; Helene Blasco; Rayomand Press; Julien Praline; Catherine Antar; Charlotte Veyrat-Durebex; Yves-Olivier Guettard; William Camu; Peter M Andersen; Patrick Vourc'h; Christian R Andres
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

Review 5.  [Progressive muscle atrophy. A rarely diagnosed variant of amyotrophic lateral sclerosis].

Authors:  T Meyer; C Münch; F K H van Landeghem; N Borisow; J Dullinger; P Linke
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

6.  Familial risks for amyotrophic lateral sclerosis and autoimmune diseases.

Authors:  Kari Hemminki; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Neurogenetics       Date:  2008-12-17       Impact factor: 2.660

7.  Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications.

Authors:  Peter M Andersen; Magdalena Kuzma-Kozakiewicz; Jürgen Keller; Helena E A Aho-Oezhan; Katarzyna Ciecwierska; Natalia Szejko; Cynthia Vázquez; Sarah Böhm; Gisela Badura-Lotter; Thomas Meyer; Susanne Petri; Katharina Linse; Andreas Hermann; Olof Semb; Erica Stenberg; Simona Nackberg; Johannes Dorst; Ingo Uttner; Ann-Cristin Häggström; Albert C Ludolph; Dorothée Lulé
Journal:  J Neurol       Date:  2018-05-04       Impact factor: 4.849

8.  Characterization of intercostal muscle pathology in canine degenerative myelopathy: a disease model for amyotrophic lateral sclerosis.

Authors:  Brandie R Morgan; Joan R Coates; Gayle C Johnson; Alyssa C Bujnak; Martin L Katz
Journal:  J Neurosci Res       Date:  2013-09-16       Impact factor: 4.164

9.  Pattern of spread and prognosis in lower limb-onset ALS.

Authors:  Martin R Turner; Alice Brockington; Jakub Scaber; Hannah Hollinger; Rachael Marsden; Pamela J Shaw; Kevin Talbot
Journal:  Amyotroph Lateral Scler       Date:  2010-08

10.  Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS.

Authors:  M R Turner; A D Osei-Lah; A Hammers; A Al-Chalabi; C E Shaw; P M Andersen; D J Brooks; P N Leigh; K R Mills
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.